IQVIA (NYSE:IQV) Downgraded by StockNews.com

StockNews.com lowered shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a research note published on Tuesday morning.

Several other brokerages also recently commented on IQV. JPMorgan Chase & Co. increased their price target on IQVIA from $260.00 to $288.00 and gave the company an overweight rating in a report on Monday, August 5th. Evercore ISI upped their price objective on shares of IQVIA from $230.00 to $270.00 and gave the stock an outperform rating in a report on Tuesday, July 23rd. Barclays lifted their target price on shares of IQVIA from $255.00 to $275.00 and gave the stock an overweight rating in a report on Tuesday, July 23rd. UBS Group upped their price target on shares of IQVIA from $295.00 to $300.00 and gave the company a buy rating in a report on Tuesday, July 23rd. Finally, Argus upgraded IQVIA to a strong-buy rating in a research note on Wednesday, July 31st. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $265.67.

IQVIA Stock Performance

Shares of IQV opened at $250.81 on Tuesday. The firm has a market cap of $45.70 billion, a price-to-earnings ratio of 34.26, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49. The company’s fifty day moving average is $229.89 and its 200-day moving average is $233.85. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA has a 12 month low of $167.42 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.22 earnings per share. Equities analysts expect that IQVIA will post 10.24 EPS for the current fiscal year.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rise Advisors LLC acquired a new stake in IQVIA in the 1st quarter valued at $31,000. Versant Capital Management Inc boosted its stake in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Riverview Trust Co bought a new stake in shares of IQVIA in the 1st quarter worth about $32,000. Opal Wealth Advisors LLC acquired a new stake in shares of IQVIA during the 2nd quarter worth about $27,000. Finally, Itau Unibanco Holding S.A. bought a new position in IQVIA during the 2nd quarter valued at about $29,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.